In the past 12 months, several developments have impacted the pharmaceutical industry relevant to products under HS Code 30029090:
1. API Price Fluctuations (June 2025): The Directorate General of Foreign Trade (DGFT) reported significant fluctuations in the prices of Active Pharmaceutical Ingredients (APIs) due to supply chain disruptions. Manufacturers are advised to monitor API prices closely to manage production costs effectively.
2. New CDSCO Guidelines (September 2025): The CDSCO issued revised guidelines for the export of pharmaceutical products, emphasizing stricter quality control measures and documentation requirements. Exporters must ensure compliance with these guidelines to avoid delays in obtaining export NOCs.
3. NPPA Price Revision (December 2025): The NPPA announced a revision of ceiling prices for certain essential medicines under the DPCO. While products under HS Code 30029090 were not directly affected, the revision reflects the authority's ongoing efforts to regulate drug prices.
4. WHO Prequalification Update (February 2026): The WHO added new products to its Prequalification Programme, expanding opportunities for manufacturers to supply medicines to international procurement agencies. Indian exporters are encouraged to seek WHO prequalification to enhance their market reach.
5. EMA Regulatory Changes (March 2026): The EMA implemented new guidelines for the assessment of biological medicines, affecting products under HS Code 30029090. Manufacturers targeting the EU market must align their regulatory submissions with these updated guidelines.
Staying informed about these developments is crucial for Indian exporters to navigate the complex regulatory landscape and maintain a competitive edge in the global pharmaceutical market.
